RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -505,132,000 | -644,371,000 | 4,323,270,000 | 815,435,000 | 1,717,032,000 |
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,577,198,000
Investing CF
$-1,213,709,000
Financing CF
$3,262,040,000
CapEx
$-10,636,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,967,289,000
Inventory
—
Receivables
$0
ST Investments
$3,122,534,000
EBIT TTM
$-1,708,943,000
Pretax Income TTM
$-1,768,285,000
Interest Exp TTM
$59,342,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $239.95B | $443.84 | — |
| GILD | GILEAD SCIENCES, INC. | $181.95B | $146.74 | — |
| ARGX | ARGENX SE | $63.26B | $1011.11 | — |
| MRNA | Moderna, Inc. | $55.45B | $138.89 | — |
| RVMD | Revolution Medicines, Inc. | $45.35B | $211.58 | — |
News headlines (Yahoo Finance, 1h cache)
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
2026-08-24 18:20 · Yahoo
Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze
2026-08-24 12:59 · Yahoo
3 potential blockbusters beyond obesity to watch
2026-08-24 09:42 · Yahoo
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
2026-08-14 23:09 · Yahoo
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript
2026-08-12 20:59 · Yahoo
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
2026-08-12 12:50 · Yahoo
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand
2026-08-12 09:11 · Yahoo
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?
2026-08-12 06:14 · Yahoo
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach
2026-08-12 02:35 · Yahoo
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?
2026-08-11 20:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.